MX355072B - Derivados de riperidina 3-espirociclicos como antagonistas de los receptores de grelina. - Google Patents

Derivados de riperidina 3-espirociclicos como antagonistas de los receptores de grelina.

Info

Publication number
MX355072B
MX355072B MX2013013950A MX2013013950A MX355072B MX 355072 B MX355072 B MX 355072B MX 2013013950 A MX2013013950 A MX 2013013950A MX 2013013950 A MX2013013950 A MX 2013013950A MX 355072 B MX355072 B MX 355072B
Authority
MX
Mexico
Prior art keywords
ghrelin receptor
derivatives
receptor agonists
piperidine derivatives
spirocyclic piperidine
Prior art date
Application number
MX2013013950A
Other languages
English (en)
Other versions
MX2013013950A (es
Inventor
Vijay Ambarkhane Ameet
Bhalay Gurdip
Beckett Martin
Dale James
Hamadi Ahmed
Mazzacani Alessandro
Mckenna Jeffrey
Thomson Christopher
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46317469&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX355072(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2013013950A publication Critical patent/MX2013013950A/es
Publication of MX355072B publication Critical patent/MX355072B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Abstract

La invención se refiere a derivados de la fórmula (I): (Ver Formula) en donde los sustituyentes son como se definen en la memoria descriptiva; a procesos para la preparación de estos derivados; a composiciones farmacéuticas que comprenden tales derivados; a estos derivados como un medicamento; y a dichos derivados para el tratamiento de un trastorno o de una enfermedad mediada por el receptor de grelina.
MX2013013950A 2011-05-27 2012-05-25 Derivados de riperidina 3-espirociclicos como antagonistas de los receptores de grelina. MX355072B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161490848P 2011-05-27 2011-05-27
US201161560960P 2011-11-17 2011-11-17
US201261642116P 2012-05-03 2012-05-03
PCT/IB2012/052649 WO2012164473A1 (en) 2011-05-27 2012-05-25 3-spirocyclic piperidine derivatives as ghrelin receptor agonists

Publications (2)

Publication Number Publication Date
MX2013013950A MX2013013950A (es) 2014-01-23
MX355072B true MX355072B (es) 2018-04-04

Family

ID=46317469

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013950A MX355072B (es) 2011-05-27 2012-05-25 Derivados de riperidina 3-espirociclicos como antagonistas de los receptores de grelina.

Country Status (21)

Country Link
US (2) US8546416B2 (es)
EP (1) EP2714690A1 (es)
JP (1) JP2014515369A (es)
KR (1) KR20140023399A (es)
CN (1) CN103562206A (es)
AP (1) AP2013007234A0 (es)
AR (1) AR086554A1 (es)
AU (1) AU2012264305A1 (es)
BR (1) BR112013030391A2 (es)
CA (1) CA2835916A1 (es)
CL (1) CL2013003211A1 (es)
CO (1) CO6811856A2 (es)
CR (1) CR20130625A (es)
EA (1) EA201391797A1 (es)
IL (1) IL229320A0 (es)
MX (1) MX355072B (es)
PE (1) PE20140610A1 (es)
SG (1) SG194616A1 (es)
TW (1) TW201302749A (es)
UY (1) UY34094A (es)
WO (1) WO2012164473A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20142443A1 (es) * 2012-05-03 2015-01-28 Novartis Ag Sal de l-malato de derivados de 2,7-diaza-espiro[4,5]dec-7-ilo y formas cristalinas de los mismos como agonistas del receptor de grelina
ES2689906T3 (es) * 2012-08-09 2018-11-16 Dynamis Therapeutics, Inc. Meglumina para reducir los niveles altos de triglicéridos
EA201691840A1 (ru) 2014-04-04 2017-03-31 Икс-Рикс, Инк. Замещенные спироциклические ингибиторы аутотаксина
JP2017532350A (ja) 2014-10-31 2017-11-02 ラクオリア創薬株式会社 グレリン受容体アゴニストとしてのテトラヒドロピラゾロピリジン誘導体
JP2020519639A (ja) * 2017-05-12 2020-07-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トリアザスピロ［４．５］デカノンによる胃不全麻痺の処置
CN111175387B (zh) * 2018-11-13 2022-06-07 成都康弘药业集团股份有限公司 一种米那普仑异构体的检测方法
CN113125583B (zh) * 2019-12-30 2022-06-21 成都百裕制药股份有限公司 一种注射用泮托拉唑钠中基因毒性杂质含量的检测方法
US20230174531A1 (en) * 2021-12-08 2023-06-08 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013696A1 (en) * 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5536716A (en) 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
ES2235171T3 (es) 1995-05-29 2005-07-01 Pfizer Inc. Dipeptidos que promueven la liberacion de la hormona de crecimiento.
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
WO1997011697A1 (en) * 1995-09-26 1997-04-03 Merck & Co., Inc. 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
US6071926A (en) 1996-05-22 2000-06-06 Arch Development Corporation Sleep quality improvement using a growth hormone secretagogue
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
ATE356139T1 (de) * 1997-06-25 2007-03-15 Pfizer Dipeptidderivate zur förderung der sekretion von wachstumshormon
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
ZA987385B (en) 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
GB9802251D0 (en) 1998-02-03 1998-04-01 Ciba Geigy Ag Organic compounds
PL202906B1 (pl) 1998-10-02 2009-08-31 Merck & Co Inc Zastosowanie antagonisty mGluR5
US6194578B1 (en) 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
EP1486498A1 (en) 1998-11-23 2004-12-15 Pfizer Products Inc. Process and intermediates for growth hormone secretagogues
GB9913079D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
DOP2001000154A (es) 2000-05-25 2002-05-15 Pfizer Prod Inc Combinación de secretagogos de hormona del crecimiento y antidepresivos
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
IL143690A0 (en) 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
GB0028702D0 (en) 2000-11-24 2001-01-10 Novartis Ag Organic compounds
PL363907A1 (en) 2001-03-26 2004-11-29 Novartis Ag Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
WO2002092556A1 (en) 2001-05-14 2002-11-21 Novartis Ag Sulfonamide derivatives
JP3894035B2 (ja) 2001-07-04 2007-03-14 東レ株式会社 炭素繊維強化基材、それからなるプリフォームおよび複合材料
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
AU2003218273A1 (en) 2002-04-10 2003-10-27 Eli Lilly And Company Stereoselective process for the synthesis of (d)-2-amino-5-phenylpentanoic or alkyl ester thereof
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
SE0201940D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
AR042206A1 (es) 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
GB0302876D0 (en) 2003-02-07 2003-03-12 Novartis Ag Organic compounds
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2004277318A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
JP2004277319A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物
MXPA05012547A (es) 2003-05-21 2006-05-25 Prosidion Ltd Inhibidores de amida de acido pirrolopiridina-2-carboxilico de fosforilasa de glucogeno.
EP1505064A1 (en) 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
CN1835753A (zh) 2003-08-12 2006-09-20 弗·哈夫曼-拉罗切有限公司 作为促皮质释放素(cfr)拮抗剂的螺－取代的四氢喹唑啉
ATE374190T1 (de) 2003-08-12 2007-10-15 Hoffmann La Roche Tetrahydrochinazolinderivate als cfr-antagonisten
EP1664010A1 (en) 2003-08-29 2006-06-07 Vernalis (R&D) Limited Sulfonamides antagonising n-type calcium channels
EP1675858A2 (en) 2003-09-03 2006-07-05 Neurogen Corporation 5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds
BRPI0414105B8 (pt) 2003-09-03 2021-05-25 Askat Inc compostos de benzimidazolona com atividade agonista do receptor 5-ht4
JP2005082508A (ja) 2003-09-05 2005-03-31 Dainippon Pharmaceut Co Ltd ２−アルコキシ−６−アミノ−５−ハロゲノ−ｎ−（１−置換−４−ピペリジニル）ピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
US20050113379A1 (en) 2003-09-05 2005-05-26 Ping Ge Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
RU2006111469A (ru) 2003-09-09 2007-10-27 Оно Фармасьютикал Ко., Лтд. (Jp) Антагонисты crf и гетеробициклические соединения
GB0322612D0 (en) 2003-09-26 2003-10-29 Novartis Ag Organic compounds
ATE427303T1 (de) 2003-09-30 2009-04-15 Janssen Pharmaceutica Nv Benzoimidazolverbindungen
JP2005104896A (ja) 2003-09-30 2005-04-21 Dainippon Pharmaceut Co Ltd ２−アルコキシ−６−アミノ−５−ハロゲノピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
CN1886389B (zh) 2003-09-30 2010-07-21 詹森药业有限公司 喹喔啉化合物
CA2543707A1 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
CA2545254A1 (en) 2003-11-10 2005-05-26 Merck & Co., Inc. Substituted triazoles as sodium channel blockers
US7208596B2 (en) 2003-11-25 2007-04-24 Bristol-Myers Squibb Pharma Company Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
WO2005054239A1 (en) 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
US7211568B2 (en) 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
JP2005206590A (ja) 2003-12-25 2005-08-04 Mitsubishi Pharma Corp ナトリウムチャネルサイト２選択的阻害剤
DE602005020580D1 (de) 2004-01-07 2010-05-27 Aryx Therapeutics Stereoisomere verbindungen und verfahren zur behandlung von erkrankungen des magen-darm-trakts und des zentralen nervensystems
ATE388146T1 (de) 2004-01-29 2008-03-15 Pfizer 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
EP1574478A1 (de) 2004-03-08 2005-09-14 Solvay Fluor GmbH Herstellung von Carbonylfluorid
UA89226C2 (en) 2004-03-25 2010-01-11 Янссен Фармацевтика Н.В. Imidazole compounds
WO2005097136A1 (en) 2004-03-29 2005-10-20 Merck & Co., Inc. Biaryl substituted pyrazinones as sodium channel blockers
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
WO2005115399A2 (en) 2004-04-16 2005-12-08 Neurogen Corporation Imidazopyrazines, imidazopyridines, ans imidazopyrimidines as crf1 receptor ligands
GB0412768D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
WO2005123718A2 (en) 2004-06-15 2005-12-29 Pfizer Japan Inc. Benzimidazolone carboxylic acid derivatives
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
WO2006023757A2 (en) 2004-08-19 2006-03-02 University Of Virginia Patent Foundation Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents
GB0420424D0 (en) 2004-09-14 2004-10-20 Ionix Pharmaceuticals Ltd Therapeutic compounds
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
JP5086091B2 (ja) 2004-11-05 2012-11-28 セラヴァンス， インコーポレーテッド ５−ｈｔ４受容体アゴニスト化合物
US7396933B2 (en) 2004-11-05 2008-07-08 Theravance, Inc. Quinolinone-carboxamide compounds
US20080269239A1 (en) 2004-11-11 2008-10-30 Argenta Discovery Ltd. Pyrimidine Compounds as Histamine Modulators
US20060111416A1 (en) 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
CN101080406A (zh) 2004-12-22 2007-11-28 施万制药 吲唑－甲酰胺化合物
EP1818061A1 (en) 2005-12-02 2007-08-15 Charite-Universitätsmedizin Berlin Use of ghrelin for stimulating hair growth
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
EP2644618B1 (en) 2007-02-09 2016-08-17 Ocera Therapeutics, Inc. tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators
US7994203B2 (en) 2008-08-06 2011-08-09 Novartis Ag Organic compounds
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
BR112012007183A2 (pt) 2009-09-30 2017-06-20 Tranzyme Pharma Inc solvato de um sal de um composto macrocíclico, forma polimórfica, processos para preparar a forma polimórfica e uma composição farmacêutica, composição farmacêutica, sal de um composto macrocíclico, e, métodos para estimular motilidade gastrintestinal, para tratar um distúrbio gastrintestinal e para tratar um indivíduo, e, kit

Also Published As

Publication number Publication date
AP2013007234A0 (en) 2013-11-30
CR20130625A (es) 2014-02-04
JP2014515369A (ja) 2014-06-30
KR20140023399A (ko) 2014-02-26
CA2835916A1 (en) 2012-12-06
SG194616A1 (en) 2013-12-30
WO2012164473A1 (en) 2012-12-06
CL2013003211A1 (es) 2014-07-04
US20120302540A1 (en) 2012-11-29
EP2714690A1 (en) 2014-04-09
UY34094A (es) 2013-01-03
MX2013013950A (es) 2014-01-23
US20130331369A1 (en) 2013-12-12
US8546416B2 (en) 2013-10-01
CN103562206A (zh) 2014-02-05
IL229320A0 (en) 2014-01-30
AR086554A1 (es) 2014-01-08
EA201391797A1 (ru) 2014-04-30
BR112013030391A2 (pt) 2016-12-13
CO6811856A2 (es) 2013-12-16
PE20140610A1 (es) 2014-05-31
AU2012264305A1 (en) 2013-11-21
TW201302749A (zh) 2013-01-16

Similar Documents

Publication Publication Date Title
NZ608116A (en) Triazine-oxadiazoles
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX2013013950A (es) Derivados de riperidina 3-espirociclicos como antagonistas de los receptores de grelina.
PH12015501289A1 (en) Novel benzimidazole derivatives as ep4 antagonists
PH12015501385A1 (en) Autotaxin inhibitors
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
IN2012DN02139A (es)
MY175854A (en) Novel quinolone derivatives
IN2014MN02598A (es)
MX2013010898A (es) Novedoso derivados de la pirimidina.
IN2015DN01119A (es)
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
PH12014502567A1 (en) Piperidine derivatives for gpr119 agonist
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MY164354A (en) Asymmetric ureas and medical uses thereof
MX2013014577A (es) Compuestos de heteroarilo como ligandos del receptor 5-ht4.
IN2014DN01629A (es)
IN2014DN06964A (es)
MX339858B (es) Compuestos novedosos como ligandos del receptor h3 de la histamina.
MX2013003202A (es) Inhibidores de oxadiazol de la produccion de leucotrienos.
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
MX2014000855A (es) Moduladores receptores de glucagon de quinolinilo.
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.

Legal Events

Date Code Title Description
FG Grant or registration